SHR-2004 for VTE Prevention After Total Knee Arthroplasty

Phase 2, randomised trial of SHR-2004 in venous thromboembolism (VTE) (4 arms), sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Primary endpoints: Incidence of composite endpoint consisting of asymptomatic DVT, confirmed symptomatic DVT, non-fatal PE and all-cause death at Day 12 and Incidence of composite endpoint of major and clinically relevant non-major bleeding at Day 12. Started Apr 2023; status: completed.